CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL

(Fred Hutchinson Cancer Research Center) In a small, early phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, experimental CAR T-cell immunotherapy developed at Seattle's Fred Hutchinson Cancer Research Center.